Table 2.

Bootstrap of Final Pyrazinamide Population Pharmacokinetic Model

	Final Full Model
Parameter	Estimate	95% CI	RSE (%)
Typical values
CL/F, L/h	3.53	3.47–3.58	0.8
Vc/F, L	33.4	32.9–33.9	0.8
DOSEF (1,500 mg)	0.80	0.78–0.81	0.9
DOSEF (2,000 mg)	0.70	0.66–0.73	2.4
MTT, h	1.31	1.24–1.36	2.0
Covariate effects
% Increase in FEMALEF	16.3	13.8–18.7	6.3
% Decrease in RACEMTT	41.8	28.9–49.2	8.4
% Decrease in FOODMTT	51.9	47.0–55.9	3.7
IIV
%CV* for IIV CL/F	25.1	23.8–26.3	2.1
%CV* for IIV of MTT	95.8	91.7–98.6	1.7
Residual variability
SD of additive residual error	0.47	0.38–0.56	8.6
% Increase in residual error	17.5	16.3–18.6	3.2

Definition of abbreviations: CI = confidence interval; CL/F = apparent clearance; CV = coefficient of variation; DOSE_{F (1,500 mg)} = apparent bioavailability of 1,500-mg dose; DOSE_{F (2,000 mg)} = apparent bioavailability of 2,000-mg dose; FEMALE_F = bioavailability for female sex; FOOD_MTT = mean transit time at fasting state; IIV = interindividual variability; MTT = mean transit time; RACE_MTT = mean transit time for Asian relative to Black and mixed race; RSE = relative SE; Vc/F = apparent volume of distribution of central compartment.

MTT = (1 + FOOD_MTT × FOOD) × (1 + RACE_MTT × RACE), where FOOD = 0 or 1 for 6-month control or two 4-month regimens, respectively; RACE = 0 or 1 for Black/mixed race or Asian race. F = (1 + FEMALE_F × FEMALE) × (DOSE_F), where FEMALE = 0 or 1 for male or female; DOSE_F was estimated separately for higher doses (e.g., 1,500 or 2,000 mg) assuming reference 1,000 mg with apparent bioavailability of 1.

^*Defined as %CV = 100 × sqrt[exp(ω²) − 1], where ω² is the variation of the interindividual random effects.